Skip to main content

Table 3 Inter-day variability of IFNγ, IL2, IFNγ + IL2 responses in the IFNγ/IL2 FluoroSpot assay

From: Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoring

Donor Antigen Day 1 Day 2 Day 3 Mean SD %CV
A
 S09 BZLF1 191 145 149 162 25.48 15.76
 S11 BZLF1 326 344 351 340 12.90 3.79
 S14 BZLF1 223 161 175 186 32.52 17.45
 S18 BZLF1 257 194 189 213 37.90 17.77
 S10 EBNA3A 27 27 19 24 4.62 18.98
 S12 EBNA3A 92 44 35 57 30.64 53.76
 S19 EBNA3A 144 127 67 113 40.45 35.90
 S15 PHA-L 304 358 311 324 29.37 9.05
 S25 PHA-L 77 88 60 75 14.11 18.81
 S26 PHA-L 214 242 297 251 42.23 16.82
Mean       27.02 20.81
B
 S09 BZLF1 69 62 67 66 3.61 5.46
 S11 BZLF1 18 20 17 18 1.53 8.33
 S14 BZLF1 48 57 62 56 7.09 12.74
 S18 BZLF1 27 29 48 35 11.59 33.43
 S10 EBNA3A 17 18 15 17 1.53 9.17
 S12 EBNA3A 33 34 29 32 2.65 8.27
 S19 EBNA3A 17 12 20 16 4.04 24.74
 S15 PHA-L 492 615 572 560 62.42 11.15
 S25 PHA-L 344 359 348 350 7.77 2.22
 S26 PHA-L 521 617 662 600 72.02 12.00
Mean       17.42 12.75
C
 S09 BZLF1 69 56 63 63 6.51 10.38
 S11 BZLF1 20 19 18 19 1.00 5.26
 S14 BZLF1 54 60 54 56 3.46 6.19
 S18 BZLF1 32 32 42 35 5.77 16.34
 S10 EBNA3A 14 13 13 13 0.58 4.33
 S12 EBNA3A 19 26 20 22 3.79 17.47
 S19 EBNA3A 12 11 14 12 1.53 12.39
 S15 PHA-L 215 276 258 250 31.34 12.55
 S25 PHA-L 50 59 47 52 6.24 12.01
 S26 PHA-L 95 130 155 127 30.14 23.79
Mean       9.04 12.07
  1. Values represent the mean number of antigen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC (stimulated with 1 µg/ml BZLF1 or EBNA3A peptide pools) or mitogen-specific IFNγ (A), IL2 (B) and IFNγ + IL2 (C) SFC/2 × 105 PBMC/5 × 104 PBMC (stimulated with 2 µg/ml PHA-L) detected on three different assay plates performed on three consecutive days
  2. SD standard deviation, CV coefficient of variation